Bio-Rad Laboratories Receives 'Hold' Rating from Analysts

Analysts split on the medical research company's stock performance outlook

Mar. 16, 2026 at 8:53am

Got story updates? Submit your updates here. ›

Bio-Rad Laboratories, Inc. (NYSE:BIO) has received a consensus 'Hold' rating from the six research firms covering the stock, according to Marketbeat Ratings. One analyst has a 'Sell' recommendation, two have 'Hold' ratings, and three have 'Buy' recommendations, with an average 12-month price target of $358.50.

Why it matters

The mixed analyst ratings and price target reflect the uncertainty around Bio-Rad Laboratories' near-term performance, as the company navigates market conditions and competitive pressures in the medical research and diagnostics industry.

The details

Several equity research analysts have recently weighed in on Bio-Rad's stock. Wall Street Zen downgraded the stock from 'Buy' to 'Hold', while Weiss Ratings maintained a 'Sell (d-)' rating on the shares.

  • Bio-Rad Laboratories reported its latest quarterly earnings on February 12, 2026.

The players

Bio-Rad Laboratories, Inc.

A global provider of life science research and clinical diagnostic products, headquartered in Hercules, California.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The mixed analyst sentiment on Bio-Rad Laboratories reflects the challenges facing the company as it navigates the competitive medical research and diagnostics industry, underscoring the need for the company to differentiate its products and services to drive long-term growth.